BACKGROUND:Nevirapine (NVP) resistance emerges in up to 70% of women exposed to single-dose (sd) NVP for prevention of mother-to-child transmission of human immunodeficiency virus (HIV). METHODS:HIV-infected pregnant women were randomized to receive sdNVP and either zidovudine/lamivudine (3TC), tenofovir/emtricitabine (FTC), or lopinavir/ritonavir for either 7 or 21 days. The primary endpoint was the emergence of new NVP resistance mutations as detected by standard population genotype at 2 and 6 weeks after treatment. Low-frequency NVP- or 3TC/FTC-resistant mutants at codons 103, 181, and 184 were sought using allele-specific polymerase chain reaction (ASP). RESULTS: Among 484 women randomized, 422 (87%) received study treatment. Four hundred twelve (98%) women had primary endpoint results available; of these, 5 (1.2%) had new NVP resistance detected by population genotype: 4 of 215 in the 7-day arms (1.9%; K103N in 4 women with Y181C, Y188C, or G190A in 3 of 4) and 1 of 197 (0.5%; V108I) in the 21-day arms (P = .37). Among women with ASP results, new NVP resistance mutations emerged significantly more often in the 7-day arms (13/74 [18%]) than in the 21-day arms (3/66 [5%], P = .019). 3TC/FTC-resistant mutants (M184V/I) emerged infrequently (7/134 [5%]), and their occurrence did not differ by arm. CONCLUSIONS: Three short-term antiretroviral strategies, begun simultaneously with the administration of sdNVP, resulted in a low rate (1.2%) of new NVP-resistance mutations when assessed at 2 and 6 weeks following completion of study treatment by standard genotype. ASP revealed that 21-day regimens were significantly better than 7-day regimens at preventing the emergence of minor NVP resistance variants. Clinical Trials Registration.NCT00099632.
RCT Entities:
BACKGROUND:Nevirapine (NVP) resistance emerges in up to 70% of women exposed to single-dose (sd) NVP for prevention of mother-to-child transmission of human immunodeficiency virus (HIV). METHODS:HIV-infected pregnant women were randomized to receive sdNVP and either zidovudine/lamivudine (3TC), tenofovir/emtricitabine (FTC), or lopinavir/ritonavir for either 7 or 21 days. The primary endpoint was the emergence of new NVP resistance mutations as detected by standard population genotype at 2 and 6 weeks after treatment. Low-frequency NVP- or 3TC/FTC-resistant mutants at codons 103, 181, and 184 were sought using allele-specific polymerase chain reaction (ASP). RESULTS: Among 484 women randomized, 422 (87%) received study treatment. Four hundred twelve (98%) women had primary endpoint results available; of these, 5 (1.2%) had new NVP resistance detected by population genotype: 4 of 215 in the 7-day arms (1.9%; K103N in 4 women with Y181C, Y188C, or G190A in 3 of 4) and 1 of 197 (0.5%; V108I) in the 21-day arms (P = .37). Among women with ASP results, new NVP resistance mutations emerged significantly more often in the 7-day arms (13/74 [18%]) than in the 21-day arms (3/66 [5%], P = .019). 3TC/FTC-resistant mutants (M184V/I) emerged infrequently (7/134 [5%]), and their occurrence did not differ by arm. CONCLUSIONS: Three short-term antiretroviral strategies, begun simultaneously with the administration of sdNVP, resulted in a low rate (1.2%) of new NVP-resistance mutations when assessed at 2 and 6 weeks following completion of study treatment by standard genotype. ASP revealed that 21-day regimens were significantly better than 7-day regimens at preventing the emergence of minor NVP resistance variants. Clinical Trials Registration.NCT00099632.
Authors: Susan H Eshleman; Laura A Guay; Anthony Mwatha; Elizabeth R Brown; Shawn P Cunningham; Philippa Musoke; Francis Mmiro; J Brooks Jackson Journal: J Acquir Immune Defic Syndr Date: 2004-02-01 Impact factor: 3.731
Authors: S Palmer; V Boltz; N Martinson; F Maldarelli; G Gray; J McIntyre; J Mellors; L Morris; J Coffin Journal: Proc Natl Acad Sci U S A Date: 2006-04-25 Impact factor: 11.205
Authors: Tamara S Flys; Shu Chen; Dana C Jones; Donald R Hoover; Jessica D Church; Susan A Fiscus; Anthony Mwatha; Laura A Guay; Francis Mmiro; Philippa Musoke; Newton Kumwenda; Taha E Taha; J Brooks Jackson; Susan H Eshleman Journal: J Acquir Immune Defic Syndr Date: 2006-08-15 Impact factor: 3.731
Authors: Sarah Palmer; Valerie F Boltz; Jeremy Y Chow; Neil A Martinson; James A McIntyre; Glenda E Gray; Mark J Hopley; Douglas Mayers; Patrick Robinson; David B Hall; Frank Maldarelli; John M Coffin; John W Mellors Journal: Antivir Ther Date: 2011-11-03
Authors: L A Guay; P Musoke; T Fleming; D Bagenda; M Allen; C Nakabiito; J Sherman; P Bakaki; C Ducar; M Deseyve; L Emel; M Mirochnick; M G Fowler; L Mofenson; P Miotti; K Dransfield; D Bray; F Mmiro; J B Jackson Journal: Lancet Date: 1999-09-04 Impact factor: 79.321
Authors: S H Eshleman; M Mracna; L A Guay; M Deseyve; S Cunningham; M Mirochnick; P Musoke; T Fleming; M Glenn Fowler; L M Mofenson; F Mmiro; J B Jackson Journal: AIDS Date: 2001-10-19 Impact factor: 4.177
Authors: M Mirochnick; T Fenton; P Gagnier; J Pav; M Gwynne; S Siminski; R S Sperling; K Beckerman; E Jimenez; R Yogev; S A Spector; J L Sullivan Journal: J Infect Dis Date: 1998-08 Impact factor: 5.226
Authors: Seble Kassaye; Esther Lee; Rami Kantor; Elizabeth Johnston; Mark Winters; Lynn Zijenah; Patrick Mateta; David Katzenstein Journal: AIDS Res Hum Retroviruses Date: 2007-08 Impact factor: 2.205
Authors: Mary A Vogler; Laura M Smeaton; Rodney L Wright; Sandra W Cardoso; Jorge Sanchez; Rosa Infante; Laura E Moran; Catherine Godfrey; Lisa M Demeter; Victoria A Johnson Journal: J Acquir Immune Defic Syndr Date: 2014-04-15 Impact factor: 3.731
Authors: Randall G Fisher; Davey M Smith; Ben Murrell; Ruhan Slabbert; Bronwyn M Kirby; Clair Edson; Mark F Cotton; Richard H Haubrich; Sergei L Kosakovsky Pond; Gert U Van Zyl Journal: J Clin Virol Date: 2014-11-20 Impact factor: 3.168
Authors: Jane Hitti; Elias K Halvas; Lu Zheng; Constantinos G Panousis; Joseph Kabanda; Frank Taulo; Nagalingeswaran Kumarasamy; Jean William Pape; Umesh Lalloo; Heather Sprenger; Karin L Klingman; Ellen S Chan; Deborah McMahon; John W Mellors Journal: J AIDS Clin Res Date: 2014-11-09